User profiles for P. Flamen

Patrick Flamen

Institut Jules Bordet
Verified email at bordet.be
Cited by 9785

Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma

P Flamen, A Lerut, E Van Cutsem… - Journal of Clinical …, 2000 - ascopubs.org
… For local LN, the sensitivity of FDG-PET was lower than EUS (33% v 81%, respectively; P =
.027), but the specificity may have been higher (89% v 67%, respectively; P = not significant […

[PDF][PDF] Prevention and treatment of complications of selective internal radiation therapy: expert guidance and systematic review

…, L Bester, JI Bilbao, DM Coldwell, P Flamen… - …, 2017 - Wiley Online Library
Selective internal radiation therapy (or radioembolization) by intra‐arterial injection of radioactive
yttrium‐90‐loaded microspheres is increasingly used for the treatment of patients with …

Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic …

…, M Paesmans, JLV Laethem, P Flamen - Journal of clinical …, 2010 - ascopubs.org
… Grade 3 or 4 toxicities were recorded in six patients after FU monotherapy and in one
patient after radioembolization plus FU treatment (P = .10). Twenty-five of 44 patients received …

[HTML][HTML] Imaging in colorectal cancer: progress and challenges for the clinicians

E Van Cutsem, HMW Verheul, P Flamen, P Rougier… - Cancers, 2016 - mdpi.com
The use of imaging in colorectal cancer (CRC) has significantly evolved over the last twenty
years, establishing important roles in surveillance, diagnosis, staging, treatment selection …

[HTML][HTML] Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer

P Flamen, E Van Cutsem, A Lerut, JP Cambier… - Annals of …, 2002 - Elsevier
… pre-CRT PET and the major response rate (P = 0.001): such response occurred in nine of 11
… (P = 0.002) than the extent of LN involvement seen on the pretreatment FDG-PET (P = 0.087…

[HTML][HTML] Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab …

…, AH Brouwers, A Awada, EGE de Vries, P Flamen - Annals of oncology, 2016 - Elsevier
Background Only human epidermal growth factor receptor (HER)2 status determined by
immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) has been validated to …

[HTML][HTML] Bone health in cancer: ESMO clinical practice guidelines

…, E Chow, E Terpos, S Oudard, Ø Bruland, P Flamen… - Annals of oncology, 2020 - Elsevier
Highlights • The clinical course of advanced cancer for many patients with bone metastases
can be transformed through optimum multidisciplinary management. • Bone-targeted agents …

The ESTRO Breur Lecture 2009. From population to voxel-based radiotherapy: exploiting intra-tumour and intra-organ heterogeneity for advanced treatment of non …

…, GAMS van Dongen, K Muylle, P Flamen… - Radiotherapy and …, 2010 - Elsevier
Evidence is accumulating that radiotherapy of non-small cell lung cancer patients can be
optimized by escalating the tumour dose until the normal tissue tolerances are met. To further …

[HTML][HTML] International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin …

…, DY Sze, BJ de Wit van der veen, P Flamen - European journal of …, 2021 - Springer
Purpose A multidisciplinary expert panel convened to formulate state-of-the-art recommendations
for optimisation of selective internal radiation therapy (SIRT) with yttrium-90 ( 90 Y)-…

Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction: a prospective study based on …

T Lerut, P Flamen, N Ectors, E Van Cutsem… - Annals of …, 2000 - journals.lww.com
Objective To assess the value of positron emission tomography with 18 fluorodeoxyglucose
(FDG-PET) for preoperative lymph node staging of patients with primary cancer of the …